Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

on for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2008 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

                          IDENIX PHARMACEUTICALS, INC.

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                     (IN THOUSANDS, EXCEPT PER SHARE DATA)

                                   (UNAUDITED)

                                     Three Months Ended      Years Ended
                                         December 31,        December 31,
                                       2008      2007      2008       2007
    Revenues:
      Collaboration revenue -
       related party                 $4,247   $12,573    $9,815    $64,751
      Other revenue                      21        29       234      3,277
        Total revenues                4,268    12,602    10,049     68,028

    Operating expenses (1):
      Cost of sales                     479     1,487     1,745      2,001
      Research and development       11,949    20,294    53,887     85,839
      Selling, general and
       administrative                 5,702     9,278    27,130     63,348
      Restructuring and
    
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Pismo Beach, CA (PRWEB) June 03, 2015 ... passed a Senate Energy, Utilities and Communications Committee (11-0) and ... the DA CAP) and renewable energy. , The Committee Chairman ... amended to increase the CAP by 8,000 GWh and would ... the utility wait list. , This “Wait List” and ...
(Date:6/3/2015)... Milan, Tennessee (PRWEB) June 03, 2015 ... facility in Milan, Tennessee to support the RCBC Waste ... Energy is fourth generation in the family business, ... since 1908. His family added recycling to their ... waste and recycling services to the Fortune 500 companies ...
(Date:6/3/2015)... June 03, 2015 Marktech Optoelectronics is ... Photodiodes. Marktech APD’s have an internal gain mechanism, fast ... the near infrared region. These APD’s are recommended for ... is needed to overcome high pre-amp noise. In addition, ... and are ideal for extreme low-level light detection and ...
(Date:6/2/2015)... TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy ... whereby the institutional investors will have the option to ... up to $4.93M in near term funding, pending closing ... restructured terms and subject to certain market conditions, the ... in a larger influx of capital to fund the ...
Breaking Biology Technology:Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2Marktech Introduces New Line of APDs 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3
... KANSAS CITY, Kansas , Aug. 5 Oncimmune® ... test that aids physicians in risk assessment and the early ... study that demonstrates the clinical validity of the test. The study ... Diagnosis " is now available on line at Annals of ...
... how a new type of experimental antibiotic can ... treatments [1]. The findings could ultimately help scientists ... responsible for many hospital and community-acquired infections. ... team of researchers from GlaxoSmithKline (GSK) captured a ...
... , Aug. 4 Forte, LLC, ... a web-based probate database and estate recovery application ... Probate Finder OnDemand provides access to a proprietary ... records, powerful matching algorithms that accurately match deceased ...
Cached Biology Technology:New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 3New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 4New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 5New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 6Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance 2Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... new, more effective and personalized cancer treatments, Horizon Discovery, ... Reserve University exclusive rights to a panel of new ... Zhenghe John Wang, assistant professor of genetics at the ... initially for 10 years and includes up-front fees and ...
... Institute at Virginia Tech have discovered how abscisic ... properties for the treatment of disease, helps fight ... published in the November 2010 Journal of ... for the development of treatments for inflammatory and ...
... Mich. The risk of esophageal cancer among patients ... as high as many may think, according to new ... considered a relative risk for developing esophageal adenocarcinoma, but ... M.D., M.Sc., an investigator with the Department of Veterans ...
Cached Biology News:Isogenic cell models for cancer research exclusively licensed to Horizon Discovery 2Researchers discover how natural drug fights inflammation 2Researchers discover how natural drug fights inflammation 3Esophageal cancer risk lower than expected for patients with GERD 2
A component of the Acridinium protein labeling kit....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
...
... calibration, and validation (MCV) plate ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
Biology Products: